Sara J Healy1, Haikady N Nagaraja2, Dhuha Alwan3, Kathleen M Dungan4. 1. Division of Endocrinology, Diabetes, and Metabolism, The Ohio State University Wexner Medical Center, 5th Floor McCampbell Hall, 1581 Dodd Drive, Columbus, OH, 43210-1296, USA. 2. Division of Biostatistics, The Ohio State University College of Public Health, Columbus, OH, 43210-1296, USA. 3. The Ohio State University College of Public Health, Columbus, OH, 43210-1296, USA. 4. Division of Endocrinology, Diabetes, and Metabolism, The Ohio State University Wexner Medical Center, 5th Floor McCampbell Hall, 1581 Dodd Drive, Columbus, OH, 43210-1296, USA. Kathleen.dungan@osumc.edu.
Abstract
PURPOSE: To determine prevalence, predictors, and outcomes of steroid-induced hyperglycemia in hospitalized patients with hematologic malignancies METHODS: We performed retrospective analysis of patients who were hospitalized on any of the four hematology services or bone marrow transplant service and who received systemic steroids during a 2-month period. Mean glucoses for days 1-4 and maximum glucose were calculated and the total daily steroid dose was converted to equivalent dose of dexamethasone. Hyperglycemia was defined as any glucose >9.917 mmol/l during days 1-4. We examined associations between variables using Spearman's correlations and multivariable linear regression RESULTS: 168 patients were included in the analysis. Mean age was 57.1 ± 14.4 years with 59% males and 90% Caucasians. The prevalence of hyperglycemia was 39%. Eight patients received intravenous insulin. In patients without diabetes, steroid dose equivalent to >12 mg dexamethasone and longer acting steroids caused greater degree of hyperglycemia compared to a dose <12 mg. Maximum glucose was a predictor of hospital length of stay among patients without diabetes (but not those with diabetes), and with acute leukemia or stem cell transplant (but not other hematologic malignancies). There were no significant differences in in mortality or other outcomes between the groups with and without hyperglycemia CONCLUSIONS: Hyperglycemia is common in patients with hematologic malignancies, which require frequent corticosteroids. Higher steroid dose and long-acting steroids caused a greater degree of hyperglycemia. Maximum glucose was a predictor of length of stay but this was only significant for patients without diabetes, those with acute hematologic malignancy or stem cell transplant.
PURPOSE: To determine prevalence, predictors, and outcomes of steroid-induced hyperglycemia in hospitalized patients with hematologic malignancies METHODS: We performed retrospective analysis of patients who were hospitalized on any of the four hematology services or bone marrow transplant service and who received systemic steroids during a 2-month period. Mean glucoses for days 1-4 and maximum glucose were calculated and the total daily steroid dose was converted to equivalent dose of dexamethasone. Hyperglycemia was defined as any glucose >9.917 mmol/l during days 1-4. We examined associations between variables using Spearman's correlations and multivariable linear regression RESULTS: 168 patients were included in the analysis. Mean age was 57.1 ± 14.4 years with 59% males and 90% Caucasians. The prevalence of hyperglycemia was 39%. Eight patients received intravenous insulin. In patients without diabetes, steroid dose equivalent to >12 mg dexamethasone and longer acting steroids caused greater degree of hyperglycemia compared to a dose <12 mg. Maximum glucose was a predictor of hospital length of stay among patients without diabetes (but not those with diabetes), and with acute leukemia or stem cell transplant (but not other hematologic malignancies). There were no significant differences in in mortality or other outcomes between the groups with and without hyperglycemia CONCLUSIONS:Hyperglycemia is common in patients with hematologic malignancies, which require frequent corticosteroids. Higher steroid dose and long-acting steroids caused a greater degree of hyperglycemia. Maximum glucose was a predictor of length of stay but this was only significant for patients without diabetes, those with acute hematologic malignancy or stem cell transplant.
Authors: A Hiraoka; Y Ohashi; S Okamoto; Y Moriyama; T Nagao; Y Kodera; A Kanamaru; H Dohy; T Masaoka Journal: Bone Marrow Transplant Date: 2001-07 Impact factor: 5.483
Authors: Christina Wei; Manigandan S Thyagiarajan; Linda P Hunt; Julian P H Shield; Michael C G Stevens; Elizabeth C Crowne Journal: Pediatr Blood Cancer Date: 2015-05-19 Impact factor: 3.167
Authors: Marilyn J Hammer; Corey Casper; Ted A Gooley; Paul V O'Donnell; Michael Boeckh; Irl B Hirsch Journal: Biol Blood Marrow Transplant Date: 2009-03 Impact factor: 5.742
Authors: Bernard Tawfik; Timothy S Pardee; Scott Isom; Sarunas Sliesoraitis; Allison Winter; Julia Lawrence; Bayard L Powell; Heidi D Klepin Journal: J Geriatr Oncol Date: 2015-10-30 Impact factor: 3.599
Authors: Mary Ann Weiser; Maria E Cabanillas; Marina Konopleva; Deborah A Thomas; Sherry A Pierce; Carmen P Escalante; Hagop M Kantarjian; Susan M O'Brien Journal: Cancer Date: 2004-03-15 Impact factor: 6.860
Authors: Netanya I Pollock; Yael Flamand; Jia Zhu; Kate Millington; Kristen Stevenson; Lewis B Silverman; Lynda M Vrooman; Laurie E Cohen Journal: Pediatr Blood Cancer Date: 2021-12-21 Impact factor: 3.838
Authors: Leah L Zullig; Anthony D Sung; Michel G Khouri; Shelley Jazowski; Nishant P Shah; Andrea Sitlinger; Dan V Blalock; Colette Whitney; Robin Kikuchi; Hayden B Bosworth; Matthew J Crowley; Karen M Goldstein; Igor Klem; Kevin C Oeffinger; Susan Dent Journal: JACC CardioOncol Date: 2022-06-21